Brokerages Set LivaNova PLC (NASDAQ:LIVN) PT at $61.17

Shares of LivaNova PLC (NASDAQ:LIVN) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are presently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $61.17.

LIVN has been the subject of a number of research reports. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price objective on shares of LivaNova in a research report on Monday, March 17th. Barclays cut their target price on shares of LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a research report on Friday, March 7th. Stifel Nicolaus cut their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Wolfe Research downgraded shares of LivaNova from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, February 26th. Finally, StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Tuesday, March 25th.

LivaNova Stock Up 5.5 %

Shares of LIVN stock opened at $35.72 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock’s 50 day simple moving average is $41.93 and its 200 day simple moving average is $47.56. The company has a market capitalization of $1.94 billion, a price-to-earnings ratio of 85.05 and a beta of 0.90. LivaNova has a twelve month low of $32.48 and a twelve month high of $64.48.

Institutional Investors Weigh In On LivaNova

Several institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Vanguard Group Inc. increased its stake in shares of LivaNova by 12.7% in the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company’s stock valued at $108,823,000 after buying an additional 265,291 shares during the period. Capital Research Global Investors increased its position in shares of LivaNova by 19.1% during the fourth quarter. Capital Research Global Investors now owns 1,612,818 shares of the company’s stock worth $74,690,000 after acquiring an additional 258,730 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of LivaNova by 0.6% in the third quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock valued at $70,676,000 after purchasing an additional 8,331 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of LivaNova by 8.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,310,990 shares of the company’s stock worth $60,710,000 after acquiring an additional 107,693 shares in the last quarter. Finally, Redmile Group LLC grew its holdings in shares of LivaNova by 19.3% in the fourth quarter. Redmile Group LLC now owns 1,043,539 shares of the company’s stock valued at $48,326,000 after acquiring an additional 168,500 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.